Dergiler / Eastern Journal of Medicine / 2017 / Cilt: 22 - Sayı: 4

Survivin expression may affect the neoadjuvant chemotherapy response in breast cancer patients

Sayfa
147–154
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

These findings must be tested with prospective clinical trials.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:To investigate whether there is a predictive effect of NF-kappaB, survivin, and Ki-67 expressions on pathological response and disease relapse in breast cancer (BC) patients.
📊
Temel Bulgular & Veri:Ki-67, survivin and NF-kappaB expressions were analyzed in the pathology specimens of breast biopsy before and after neoadjuvant chemotherapy (NeoCT) in BC patients (n=52).
💡
Sonuç & Katkı:These findings must be tested with prospective clinical trials.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

To investigate whether there is a predictive effect of NF-kappaB, survivin, and Ki-67 expressions on pathological response and disease relapse in breast cancer (BC) patients. Ki-67, survivin and NF-kappaB expressions were analyzed in the pathology specimens of breast biopsy before and after neoadjuvant chemotherapy (NeoCT) in BC patients (n=52). Event -free survival (EFS) (defined as recurrence or metastasis free) analyze was performed. The median overall survival was 43.5 months and the median EFS was 51 months (95% CI: 33.3-68.9) in all patients. The expression percentages of NF-kappaB, survivin, and Ki-67 significantly decreased after NeoCT (p<0.001). Survivin expression level before NeoCT was significantly higher in patients who did not respond to NeoCT than both partial-responders and complete-responders (p=0.038, p=0.010, respectively). Type of NeoCT was the only independent factor on pathological response status (p=0.007). Addition of taxanes to NeoCT improved pathological complete response rates about six times. However, no predictor was found to be a prognostic factor for EFS in multivariate analyze. Higher survivin expression level before NeoCT may be associated with poor pathological response to NeoCT. These findings must be tested with prospective clinical trials.

🔖

Bu Makaleye Atıf Yap

ER, Z., PEŞTERELİ, H. E., TAVLI, L., BOZCUK, H., ERDOĞAN, G., ESEN, H. H., ARTAÇ, M., KORKMAZ, L., GÜNDÜZ, Ş., KARAAĞAÇ, M., DEMİRCİOĞLU, S. (2017). Survivin expression may affect the neoadjuvant chemotherapy response in breast cancer patients. Eastern Journal of Medicine, Cilt: 22 - Sayı: 4, 147–154. https://ajindex.com/articles/205767

Kaynakça (14)

  1. Hidalgo JV, Bronsert P, Orlowska-Volk M, et al. Histological Analysis of ?? T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. Front Immunol 2014; 5: 632
  2. Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol 2013; 717: 58-66
  3. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-888
  4. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004; 136: 416-425
  5. Gionet N, Jansson D, Mader S, Pratt MA. NFkappaB and estrogen receptor alpha interactions: Differential function in estrogen receptornegative and -positive hormone-independent breast cancer cells. J Cell Biochem 2009; 107: 448-459
  6. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272: 14914-14920
  7. Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006; 13: 607-616
  8. Jones RL, Rojo F, A'Hern R, et al. Nuclear NF?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol 2011; 64: 130-135
  9. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921
  10. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244: 164-171
  11. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA, Shroyer KR. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol 2004; 12: 296-304
  12. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562-4574
  13. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large populationbased cohort of a cancer registry. Breast Cancer Res Treat 2013; 139: 539-552
  14. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki67, HER-2 and topoisomerase II alpha status as predictiv